keyword
MENU ▼
Read by QxMD icon Read
search

Oral antidiabetics chronic kidney disease

keyword
https://www.readbyqxmd.com/read/27770799/correction-of-metabolic-acidosis-improves-insulin-resistance-in-chronic-kidney-disease
#1
Antonio Bellasi, Lucia Di Micco, Domenico Santoro, Stefania Marzocco, Emanuele De Simone, Mario Cozzolino, Luca Di Lullo, Pasquale Guastaferro, Biagio Di Iorio
BACKGROUND: Correction of metabolic acidosis (MA) with nutritional therapy or bicarbonate administration is widely used in chronic kidney disease (CKD) patients. However, it is unknown whether these interventions reduce insulin resistance (IR) in diabetic patients with CKD. We sought to evaluate the effect of MA correction on endogenous insulin action in diabetic type 2 (DM2) CKD patients. METHODS: A total of 145 CKD subjects (83 men e 62 women) with DM2 treated with oral antidiabetic drugs were included in the study and followed up to 1 year...
October 22, 2016: BMC Nephrology
https://www.readbyqxmd.com/read/27320184/leader-6-baseline-renal-function-and-associated-factors-in-a-high-cardiovascular-risk-type-2-diabetes-population
#2
Ilhan Satman, Rosangela R Rea, Mats Eriksson, Ofri Mosenzon, Richard Pratley, Florian M Baeres, David D Ørsted, Johannes F Mann
AIMS: To examine the prevalence of chronic kidney disease (CKD) and its associated factors in a multinational population with type 2 diabetes mellitus (T2DM) and prior cardiovascular disease (CVD). METHODS: The LEADER trial randomized 9340 participants-81.3% with prior CVD at baseline. CKD was defined as estimated GFR <60ml/min/1.73m(2) and/or an albumin-to-creatinine ratio ≥3.0mg/mmol. RESULTS: At baseline, 51.9% of participants with prior CVD had CKD...
June 3, 2016: Journal of Diabetes and its Complications
https://www.readbyqxmd.com/read/27084800/the-extra-phosphate-intestinal-load-from-medications-is-it-a-real-concern
#3
Adamasco Cupisti, Diego Moriconi, Claudia D'Alessandro, Francesco Verde, Michele Marchini, Alessandro Saba, Maria Francesca Egidi
BACKGROUND AND AIMS: Reduction of intestinal load of phosphorus is important for the prevention and treatment of chronic kidney disease (CKD)-mineral and bone disorder (MBD). However, this strategy is limited by patients' poor adherence to dietary prescription and by the existence of hidden sources of phosphorus. In addition to food containing phosphate-based additives, it was recently claimed that medications may contribute to increase the load of phosphate (P), mainly present as an excipient...
April 15, 2016: Journal of Nephrology
https://www.readbyqxmd.com/read/27055204/managing-diabetes-in-hospitalized-patients-with-chronic-kidney-disease
#4
REVIEW
Shridhar N Iyer, Robert J Tanenberg
Because few randomized trials have been done, little is known about appropriate glycemic control in hospitalized patients with chronic kidney disease (CKD) and diabetes mellitus. These patients are at high risk of hypoglycemia. It is prudent to monitor glucose closely, set less-stringent blood sugar goals, avoid oral antidiabetic agents, and possibly reduce insulin dosage.
April 2016: Cleveland Clinic Journal of Medicine
https://www.readbyqxmd.com/read/26944432/antidiabetic-efficacy-of-citronellol-a-citrus-monoterpene-by-ameliorating-the-hepatic-key-enzymes-of-carbohydrate-metabolism-in-streptozotocin-induced-diabetic-rats
#5
Subramani Srinivasan, Udaiyar Muruganathan
Diabetes mellitus is a clinically complex disease characterized by chronic hyperglycemia with metabolic disturbances. During diabetes, endogenous hepatic glucose production is increased as a result of impaired activities of the key enzymes of carbohydrate metabolism. The purpose of the present study was to evaluate the antidiabetic efficacy of citronellol, a citrus monoterpene in streptozotocin (STZ)-induced diabetic rats. Diabetes mellitus was induced by a single intraperitoneal injection of STZ (40 mg/kg b...
April 25, 2016: Chemico-biological Interactions
https://www.readbyqxmd.com/read/26900098/oral-antidiabetics-use-among-diabetic-type-2-patients-with-chronic-kidney-disease-do-nephrologists-take-account-of-recommendations
#6
Clotilde Muller, Yves Dimitrov, Olivier Imhoff, Sarah Richter, Julien Ott, Thierry Krummel, Dorothée Bazin-Kara, Francois Chantrel, Thierry Hannedouche
BACKGROUND: There is an increasing prevalence of diabetes type 2 and chronic kidney disease, challenging appropriate prescribing of oral anti-diabetic drugs (OADs). METHODS: We have described the practice patterns of 13 nephrologists in 4 centers, in a cohort of 301 consecutive adult type 2 diabetic patients. Among oral anti-diabetic prescriptions, we have detailed drugs dosage for each subject, with 3 different formulae for estimating glomerular filtration rate (GFR) and its adequation according to the latest ERBP recommendations (2015)...
May 2016: Journal of Diabetes and its Complications
https://www.readbyqxmd.com/read/26872083/management-of-diabetes-mellitus-in-individuals-with-chronic-kidney-disease-therapeutic-perspectives-and-glycemic-control
#7
REVIEW
Carolina C R Betônico, Silvia M O Titan, Maria Lúcia C Correa-Giannella, Márcia Nery, Márcia Queiroz
The purpose of this study was to evaluate the therapeutic options for diabetes treatment and their potential side effects, in addition to analyzing the risks and benefits of tight glycemic control in patients with diabetic kidney disease. For this review, a search was performed using several pre-defined keyword combinations and their equivalents: "diabetes kidney disease" and "renal failure" in combination with "diabetes treatment" and "oral antidiabetic drugs" or "oral hypoglycemic agents." The search was performed in PubMed, Endocrine Abstracts and the Cochrane Library from January 1980 up to January 2015...
January 2016: Clinics
https://www.readbyqxmd.com/read/26867302/-how-i-treat-the-role-of-dpp-4-inhibitors-gliptins-in-the-treatment-of-type-2-diabetes
#8
A J Scheen
Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are more and more prominent medications in the management of type 2 diabetes (T2D), with five molecules commercialized and as many fixed-dose combinations with metformin. After failure of metformin monotherapy, gliptins compete with old medications such as sulphonylureas, on the one hand, or with new oral antidiabetic agents such as inhibitors of renal sodium-glucose cotransporters type 2 (SGLT2) (gliflozines), on the other hand. Another alternative is the use of an incretin mimetic (agonist of glucagon-like peptide-1 receptors, to be injected subcutaneously) rather than an incretin enhancer such as a gliptin, before considering insulin therapy...
December 2015: Revue Médicale de Liège
https://www.readbyqxmd.com/read/26857244/a-multicenter-epidemiological-study-of-the-treatment-patterns-comorbidities-and-hypoglycemia-events-of-patients-with-type-2-diabetes-and-moderate-or-severe-chronic-kidney-disease-the-learn-study
#9
Grigorios Rombopoulos, Elena Panitti, Christos Varounis, Christos Katsinas, Ioannis Stefanidis, Dimitrios Goumenos
Objective Management of patients with type 2 diabetes (T2DM) and stage 3 to 5 chronic kidney disease (CKD) is challenging. The aim of the 'LEARN' study was to describe treatment patterns employed in this population and to record comorbidities, glycemic control and hypoglycemia episodes in routine clinical practice in Greece. Research design and methods 'LEARN' was a non-interventional, multicenter, cross-sectional study conducted in Greece between 15 February 2013 and 4 July 2013. A total of 120 adult patients were enrolled from four hospital sites in different geographic regions of Greece...
May 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/26480253/-anti-diabetics-and-chronic-kidney-disease
#10
Carlo Garofalo, Nicolangelo Iazzetta, Andrea Camocardi, Mario Pacilio, Carmela Iodice, Roberto Minutolo, Luca De Nicola, Giuseppe Conte
Diabetes mellitus (DM) is the most important non-communicable disease after hypertension. Prevalence of type 2 DM has progressively increased over the last decades. In Italy, 11.8% of the general adult population can be identified as diabetic. The major complication of DM is diabetic nephropathy (DM-CKD), which develops in approximately one-third of diabetics. Achieving optimal glycemic control is the first therapeutic goal in the management of DM-CKD. In recent years, new antidiabetic drugs have been marketed (GLP1 analogues, DPP-4 inhibitors, SGLT-2 inhibitors) to ameliorate glycemia in patients nave or treated by means of traditional agents, such as sulfonylureas, metformin, glinides, insulin...
September 2015: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/26023019/dpp-4-inhibitors-in-diabetic-patients-with-chronic-kidney-disease-and-end-stage-kidney-disease-on-dialysis-in-clinical-practice
#11
Masanori Abe, Kazuyoshi Okada
Numerous drugs with different mechanisms of action and different pharmacologic profiles are being used with the aim of improving glycemic control in patients with type 2 diabetes. The therapeutic options for patients with type 2 diabetes and chronic kidney disease (CKD) are limited because the patients' reduced glomerular filtration rate results in the accumulation of certain drugs and/or their metabolites. Although recommended oral antidiabetic agents for patients with CKD differ between countries, all of the currently available dipeptidyl peptidase-4 (DPP-4) inhibitors can be used in not only patients with CKD but also patients with end-stage kidney disease on dialysis, and these inhibitors' use is increasing...
2015: Contributions to Nephrology
https://www.readbyqxmd.com/read/25999728/management-of-patients-with-type-2-diabetes-and-mild-moderate-renal-impairment-profile-of-linagliptin
#12
REVIEW
Baptist Gallwitz
Dipeptidyl-peptidase-IV (DPP-4) inhibitors are oral antidiabetic agents that can be administered as monotherapy in patients with contraindications to metformin or metformin intolerance, and in combination with other oral compounds and/or insulin. DPP-4 inhibitors act in a glucose-dependent manner and only increase insulin secretion and inhibit glucagon secretion under hyperglycemic conditions. Renal impairment is frequent in type 2 diabetes as a result of microvascular complications and diabetes treatment, and options in these patients are limited...
2015: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/25817734/estimating-kidney-function-and-use-of-oral-antidiabetic-drugs-in-elderly
#13
COMPARATIVE STUDY
Antonios Douros, Natalie Ebert, Olga Jakob, Peter Martus, Reinhold Kreutz, Elke Schaeffner
The prevalence of diabetes mellitus (DM) and renal impairment rises with age making regular estimation of glomerular filtration rate (eGFR) in older diabetics necessary. This study investigated the differences among available estimating equations in assessing eGFR in older diabetics and examined the use of oral antidiabetic drugs (OADs) in relation to renal function. Patients with DM were participants of the Berlin Initiative Study (BIS), a population-based cohort study initiated in 2009 in Berlin, Germany, to evaluate kidney function in people ≥70 years...
June 2015: Fundamental & Clinical Pharmacology
https://www.readbyqxmd.com/read/25331711/pharmacokinetics-and-clinical-use-of-incretin-based-therapies-in-patients-with-chronic-kidney-disease-and-type%C3%A2-2-diabetes
#14
REVIEW
André J Scheen
The prevalence of chronic kidney disease (CKD) of stages 3-5 (glomerular filtration rate [GFR] <60 mL/min) is about 25-30 % in patients with type 2 diabetes mellitus (T2DM). While most oral antidiabetic agents have limitations in patients with CKD, incretin-based therapies are increasingly used for the management of T2DM. This review analyses (1) the influence of CKD on the pharmacokinetics of dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists; and (2) the efficacy/safety profile of these agents in clinical practice when prescribed in patients with both T2DM and CKD...
January 2015: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/24721942/prescription-of-oral-antidiabetic-drugs-in-k-digo-chronic-kidney-disease-stage-3-and-4-a-single-centre-report
#15
F Fabbian, A De Giorgi, M Monesi, R Tiseo, A Storari, A Mallozzi Menegatti, M Pala, F Tomasi, F Portaluppi, R Manfredini
AIM: Evaluation of chronic kidney disease (CKD) is essential in order to prescribe properly oral antidiabetic drugs (OADs). The aim of our study was to report hypoglycemic drugs prescription to CKD in a cohort of type 2 diabetes mellitus (DM) outpatients. METHODS: This survey included 1686 outpatients with type 2 DM treated with OADs who were not taking insulin evaluated by a team of diabetologists. Glomerular filtration rate (GFR) was calculated by the CKD-EPI formula and subjects were classified in the K/DIGO stages...
March 2014: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
https://www.readbyqxmd.com/read/24719761/evaluation-of-the-prevalence-of-chronic-kidney-disease-and-rates-of-oral-antidiabetic-prescribing-in-accordance-with-guidelines-and-manufacturer-recommendations-in-type-2-diabetic-patients-within-a-long-term-care-setting
#16
Ning Wu, Xia Yu, Mallik Greene, Gary Oderda
This retrospective study assessed the prevalence of moderate to severe chronic kidney disease (CKD) among nursing home (NH) residents with type 2 diabetes. The pattern of oral antidiabetic drug (OAD) use and their concordance with the National Kidney Foundation (NKF) guideline and prescribing information (PI) was also assessed. About half (47%) of diabetic residents had moderate to severe CKD. A little over a quarter of the 186 residents using OADs received at least one NKF-discordant OAD prescription. Metformin was the most commonly misused OAD...
2014: International Journal of Nephrology
https://www.readbyqxmd.com/read/24599253/metformin-and-other-antidiabetic-agents-in-renal-failure-patients
#17
REVIEW
Jean-Daniel Lalau, Paul Arnouts, Adnan Sharif, Marc E De Broe
This review mainly focuses on metformin, and considers oral antidiabetic therapy in kidney transplant patients and the potential benefits and risks of antidiabetic agents other than metformin in patients with chronic kidney disease (CKD). In view of the debate concerning lactic acidosis associated with metformin, this review tries to solve a paradox: metformin should be prescribed more widely because of its beneficial effects, but also less widely because of the increasing prevalence of contraindications to metformin, such as reduced renal function...
February 2015: Kidney International
https://www.readbyqxmd.com/read/24443793/modeling-effects-of-sglt-2-inhibitor-dapagliflozin-treatment-versus-standard-diabetes-therapy-on-cardiovascular-and-microvascular-outcomes
#18
COMPARATIVE STUDY
J Dziuba, P Alperin, J Racketa, U Iloeje, D Goswami, E Hardy, I Perlstein, H L Grossman, M Cohen
AIMS: Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor, has been shown to lower glycated hemoglobin (HbA1c), weight, blood pressure and serum uric acid in clinical trials. Plasma lipids were also evaluated as exploratory variables. The goal of this study was to estimate the long-term cardiovascular (CV) and microvascular outcomes of dapagliflozin added to the standard of care (SOC) versus SOC using simulation methodology. METHODS: The Archimedes Model, a validated model of human physiology, diseases and healthcare systems, was used to model a type 2 diabetes mellitus (T2DM) population derived from National Health and Nutrition Examination Survey (NHANES) with HbA1c 7-10%, taking a single oral antidiabetic agent [metformin, sulfonylureas SU or thiazolidinedione (TZD)] at the beginning of the trial...
July 2014: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/24299454/lactic-acidosis-induced-by-metformin-in-a-chronic-hemodialysis-patient-with-diabetes-mellitus-type-2
#19
Eda Altun, Bülent Kaya, Saime Paydaş, Barış Sarıakçalı, Ibrahim Karayaylalı
Metformin is a biguanide group oral antidiabetic drug used for the treatment of type 2 diabetes mellitus. Nausea, vomiting, diarrhea, abdominal pain, and anorexia are the most common adverse effects encountered during treatment. Lactic acidosis is a serious side effect seen with metformin use, and while the incidence of lactic acidosis is similar to other oral antidiabetics, metformin is not recommended to patients with certain risk factors, such as cardiovascular, pulmonary, and renal and liver failure. We describe a chronic hemodialysis patient treated with metformin, presenting to the nephrology department with altered mental status...
April 2014: Hemodialysis International
https://www.readbyqxmd.com/read/24287690/the-dipeptidyl-peptidase-dpp-4-inhibitors-for-type-2-diabetes-mellitus-in-challenging-patient-groups
#20
REVIEW
David Kountz
Treating hyperglycemia is a critical aspect of managing type 2 diabetes mellitus (T2DM), but can be especially challenging in patients from vulnerable groups such as those with chronic kidney disease, African Americans, and older people. The dipeptidyl peptidase (DPP)-4 inhibitors are relatively new oral antidiabetes drugs that have been incorporated into treatment algorithms over the past few years and have also been studied in these vulnerable patients. Clinical trials with DPP-4 inhibitors have now been reported for all these patient groups and have demonstrated significant improvements in measures of hyperglycemia, with a good safety profile...
December 2013: Advances in Therapy
keyword
keyword
59134
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"